- Business Wire•yesterday
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter on Wednesday, November 2, 2016, after the U.S.
- Business Wire•2 days agoSHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Khang & Khang LLP announces that it is investigating claims against Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws.
- Benzinga•3 days ago
Piper Jaffray reiterated its Overweight rating and $106 target price on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) despite discontinuation of ENDEAVOUR trial of Revusiran as it sees value in the company’s ...
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||35.50 x 200|
|Ask||37.90 x 100|
|Day's Range||35.99 - 38.60|
|52wk Range||33.16 - 110.75|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.54|
|Avg Vol (3m)||1,133,081|
|Dividend & Yield||N/A (N/A)|